UPLC-MS based integrated plasma proteomic and metabolomic profiling of TSC-RAML and its relationship with everolimus treatment

Aim: To profile the plasma proteomics and metabolomics of patients with renal cysts, sporadic angiomyolipoma (S-AML) and tuberous sclerosis complex related angiomyolipoma (TSC-RAML) before and after everolimus treatment, and to find potential diagnostic and prognostic biomarkers as well as reveal the underlying mechanism of TSC tumorigenesis.Materials and Methods: We retrospectively measured the plasma proteins and metabolites from November 2016 to November 2017 in a cohort of pre-treatment and post-treatment TSC-RAML patients and compared them with renal cyst and S-AML patients by ultra-performance liquid chromatography-mass spectrometer (UPLC-MS). The tumor reduction rates of TSC-RAML were assessed and correlated with the plasma protein and metabolite levels. In addition, functional analysis based on differentially expressed molecules was performed to reveal the underlying mechanisms.Results: Eighty-five patients with one hundred and ten plasma samples were enrolled in our study. Multiple proteins and metabolites, such as pre-melanosome protein (PMEL) and S-adenosylmethionine (SAM), demonstrated both diagnostic and prognostic effects. Functional analysis revealed many dysregulated pathways, including angiogenesis synthesis, smooth muscle proliferation and migration, amino acid metabolism and glycerophospholipid metabolism.Conclusion: The plasma proteomics and metabolomics pattern of TSC-RAML was clearly different from that of other renal tumors, and the differentially expressed plasma molecules could be used as prognostic and diagnostic biomarkers. The dysregulated pathways, such as angiogenesis and amino acid metabolism, may shed new light on the treatment of TSC-RAML.

[1]  X. Liu,et al.  A multi-omics study of diagnostic markers and the unique inflammatory tumor micro-environment involved in tuberous sclerosis complex-related renal angiomyolipoma , 2022, International journal of oncology.

[2]  Xu Wang,et al.  Analysis of renal lesions in Chinese tuberous sclerosis complex patients with different types of TSC gene mutations , 2022, Genetics and molecular biology.

[3]  T. Inada,et al.  mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine , 2022, The Journal of biological chemistry.

[4]  Nagaraj Nagathihalli,et al.  Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress , 2021, Cancers.

[5]  H. Link,et al.  Metabolome and proteome analyses reveal transcriptional misregulation in glycolysis of engineered E. coli , 2021, Nature Communications.

[6]  Trevor J Pugh,et al.  Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape , 2021, Nature Communications.

[7]  Y. Yen,et al.  Arginine Signaling and Cancer Metabolism , 2021, Cancers.

[8]  D. Sabatini,et al.  Limited survival and impaired hepatic fasting metabolism in mice with constitutive Rag GTPase signaling , 2021, Nature communications.

[9]  P. Pevzner,et al.  Integrating genomics and metabolomics for scalable non-ribosomal peptide discovery , 2021, Nature Communications.

[10]  D. Koya,et al.  Effect of Methionine Restriction on Aging: Its Relationship to Oxidative Stress , 2021, Biomedicines.

[11]  W. Liu,et al.  MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. , 2021, Cancer cell.

[12]  K. Elder,et al.  Methylation: An Ineluctable Biochemical and Physiological Process Essential to the Transmission of Life , 2020, International journal of molecular sciences.

[13]  R. Elango.  Methionine Nutrition and Metabolism: Insights from Animal Studies to Inform Human Nutrition. , 2020, The Journal of nutrition.

[14]  Jingtao Li,et al.  Glutamine relieves oxidative stress through PI3K/Akt signaling pathway in DSS-induced ulcerative colitis mice , 2020, Iranian journal of basic medical sciences.

[15]  E. Petricoin,et al.  Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies , 2020, Cancers.

[16]  Lu Gao,et al.  UPLC-MS/MS-based lipidomic profiles revealed aberrant lipids associated with invasiveness of silent corticotroph adenoma. , 2020, The Journal of clinical endocrinology and metabolism.

[17]  I. Lindberg,et al.  Increased expression and retention of the secretory chaperone proSAAS following cell stress , 2020, Cell Stress and Chaperones.

[18]  D. Kwiatkowski,et al.  Single Cell Transcriptomic Analysis Identifies a Unique Pulmonary Lymphangioleiomyomatosis Cell. , 2020, American journal of respiratory and critical care medicine.

[19]  L. Bottolo,et al.  Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis , 2020, Thorax.

[20]  E. Markert,et al.  2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer , 2020, Nature Communications.

[21]  P. Kaiser.  Methionine Dependence of Cancer , 2020, Biomolecules.

[22]  D. Lawlor,et al.  A maternal serum metabolite ratio predicts fetal growth restriction at term , 2020, Nature Medicine.

[23]  V. Krymskaya,et al.  Adoptive T Cell Transfer to Treat Lymphangioleiomyomatosis. , 2020, American journal of respiratory cell and molecular biology.

[24]  Q. Chu.  Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion , 2020, Therapeutic advances in medical oncology.

[25]  D. Fabbro,et al.  PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases , 2019, International journal of molecular sciences.

[26]  L. Devi,et al.  Opioid-Induced Signaling and Antinociception Are Modulated by the Recently Deorphanized Receptor, GPR171 , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[27]  X. Liu,et al.  UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma , 2019, BMC Cancer.

[28]  N. Restifo,et al.  An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. , 2019, JCI insight.

[29]  Payam Emami Khoonsari,et al.  Systematic analysis of the cerebrospinal fluid proteome of fibromyalgia patients. , 2019, Journal of proteomics.

[30]  Dong Ik Lee,et al.  PKG-Modified TSC2 Regulates mTORC1 Activity to Counter Adverse Cardiac Stress , 2018, Nature.

[31]  C. Carvalho,et al.  Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center , 2019, Lung.

[32]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[33]  E. Henske,et al.  Renal disease in tuberous sclerosis complex: pathogenesis and therapy , 2018, Nature Reviews Nephrology.

[34]  W. M. van der Flier,et al.  Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach , 2018, Alzheimer's & Dementia.

[35]  E. O’Shea,et al.  Translational Control through Differential Ribosome Pausing during Amino Acid Limitation in Mammalian Cells. , 2018, Molecular cell.

[36]  Hao Sun,et al.  Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial , 2018, Orphanet Journal of Rare Diseases.

[37]  D. Sabatini,et al.  The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway. , 2017, Cell metabolism.

[38]  J. Sampson,et al.  Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2 , 2017 .

[39]  J. Osborne,et al.  Causes of mortality in individuals with tuberous sclerosis complex , 2017, Developmental medicine and child neurology.

[40]  A. Venyo.  A Review of the Literature on Extrarenal Retroperitoneal Angiomyolipoma , 2016, International journal of surgical oncology.

[41]  E. Thiele,et al.  Tuberous Sclerosis Complex , 2019, Harper's Textbook of Pediatric Dermatology.

[42]  P. J. Vries,et al.  Neurological and neuropsychiatric aspects of tuberous sclerosis complex , 2015, The Lancet Neurology.

[43]  O. Larsson,et al.  mTOR coordinates protein synthesis, mitochondrial activity and proliferation , 2015, Cell cycle.

[44]  W. Stanford,et al.  The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis , 2014, Front. Cell Dev. Biol..

[45]  A. Tee,et al.  mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 , 2014, Oncogene.

[46]  C. Der,et al.  Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. , 2014, Molecular cell.

[47]  G. Raposo,et al.  PMEL: a pigment cell‐specific model for functional amyloid formation , 2013, Pigment cell & melanoma research.

[48]  N. Pavletich,et al.  mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain , 2013, Nature.

[49]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[50]  A. Sagalowsky,et al.  Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis , 2013, PloS one.

[51]  P. Zhang,et al.  The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). , 2013, Respiratory medicine.

[52]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[53]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[54]  Peter Langfelder,et al.  Fast R Functions for Robust Correlations and Hierarchical Clustering. , 2012, Journal of statistical software.

[55]  J. Manola,et al.  Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease , 2011, PloS one.

[56]  W. Cong,et al.  Angiogenesis and lymphangiogenesis in sporadic hepatic angiomyolipoma. , 2011, Pathology, research and practice.

[57]  Rodney J Hicks,et al.  In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer , 2011, Molecular Cancer Therapeutics.

[58]  J. Krischer,et al.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[59]  A. Byars,et al.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.

[60]  W. Linehan,et al.  Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. , 2010, Chest.

[61]  Chelsey Woodrum,et al.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors , 2010, Journal of Translational Medicine.

[62]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[63]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[64]  D. Brat,et al.  Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. , 2002, Journal of the American Academy of Dermatology.

[65]  A. Gown,et al.  Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphologic spectrum. , 2001, Archives of pathology & laboratory medicine.

[66]  C. Crowson,et al.  Causes of death in patients with tuberous sclerosis. , 1991, Mayo Clinic proceedings.